Merck (MRK) announced the completion of the Verona Pharma (VRNA) acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Verona gets England, Wales high court approval for acquisition by Merck
- Merck initiates three Phase 2b trials evaluating tulisokibart
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
- Closing Bell Movers: Bentley Systems up 5% on S&P MidCap 400 entry